Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)

SHE:002390 Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Net Income	127.7	120.29	101.38	287.23	224.37	272.87
Depreciation & Amortization	198.08	198.08	218.1	236.71	243.55	247.33
Other Amortization	18.46	18.46	16.89	19.12	26	28.26
Loss (Gain) From Sale of Assets	3.48	3.48	2.29	-0.02	0	0.42
Asset Writedown & Restructuring Costs	12.63	12.63	1.11	0.56	2.13	4.04
Loss (Gain) From Sale of Investments	-19.74	-19.74	-2.93	-9.4	-37.43	-3.92
Provision & Write-off of Bad Debts	24.58	24.58	49.57	64.92	40.61	26.68
Other Operating Activities	154.8	171.72	102.8	108.47	127.69	204.77
Change in Accounts Receivable	288.64	288.64	334.13	103.29	94.98	-609.77
Change in Inventory	147.63	147.63	-63.64	24.42	-97.01	-92.31
Change in Accounts Payable	-204.41	-204.41	-116.89	-33.65	-108.32	372.58
Change in Other Net Operating Assets	-	-	-	-	80.84	16.13
Operating Cash Flow	723.02	732.53	634.97	790.62	590.8	457.97
Operating Cash Flow Growth	5.18%	15.37%	-19.69%	33.82%	29.00%	-38.29%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Capital Expenditures	-52.41	-85.42	-124.87	-135.78	-158.78	-253.76
Sale of Property, Plant & Equipment	6.61	6.33	2.65	134.98	0.55	0.87
Cash Acquisitions	-	-	-	-	-	-296.17
Divestitures	-	-	-	36.55	1.61	0.68
Investment in Securities	20.74	20.74	3.1	3.07	4.63	-242.55
Other Investing Activities	20.77	19.83	4.08	11.44	33.97	46.59
Investing Cash Flow	-4.29	-38.51	-115.03	50.26	-118.02	-744.34

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Short-Term Debt Issued	-	-	-	1,211	1,985	2,112
Long-Term Debt Issued	-	440	895.1	-	-	-
Total Debt Issued	405	440	895.1	1,211	1,985	2,112
Short-Term Debt Repaid	-	-	-	-1,817	-2,019	-4,257
Long-Term Debt Repaid	-	-766.2	-900.1	-	-	-
Total Debt Repaid	-764.2	-766.2	-900.1	-1,817	-2,019	-4,257
Net Debt Issued (Repaid)	-359.2	-326.2	-5	-606.19	-34.1	-2,145
Issuance of Common Stock	-	-	-	-	-	1,505
Repurchase of Common Stock	-8.95	-8.95	-78.99	-141.4	-	-
Common Dividends Paid	-130.03	-130.82	-192.29	-158.23	-168.36	-230.34
Other Financing Activities	-36.71	-121.24	-41.63	-1.38	13.03	-39.76
Financing Cash Flow	-534.89	-587.21	-317.91	-907.2	-189.42	-910.57

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Foreign Exchange Rate Adjustments	0	0	-0	0	0	-0
Net Cash Flow	183.84	106.81	202.03	-66.32	283.35	-1,197

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Free Cash Flow	670.61	647.11	510.1	654.84	432.02	204.21
Free Cash Flow Growth	13.94%	26.86%	-22.10%	51.58%	111.56%	-66.19%
Free Cash Flow Margin	12.32%	11.52%	8.46%	10.13%	6.80%	3.16%
Free Cash Flow Per Share	0.35	0.34	0.27	0.34	0.23	0.11
Levered Free Cash Flow	737.37	696.72	597.17	569.17	314.65	-37.54
Unlevered Free Cash Flow	747.36	708.25	611.88	593.98	347.02	25.08

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash Income Tax Paid	250.46	243.52	222.01	236.11	227.09	258.49
Change in Working Capital	203.04	203.04	145.76	83.02	-36.13	-322.49

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error